Table 1.
Domain | Variables | Mean (SD) / N (%) |
---|---|---|
Demographic Characteristics | Age | 60.35 (16.07) |
Male (%) | 113 (65.3%) | |
White | 110 (64.6%) | |
Clinical Characteristics | Charlson Comorbidity Index | 2.45 (1.52) |
Body Mass Index | 30.72 (8.03) | |
NYHA Classification | ||
I | 5 (2.9%) | |
II | 95 (54.9%) | |
III | 61 (35.3%) | |
IV | 12 (6.9%) | |
Bodily Pain | 8.02 (2.72) | |
Nighttime Sleep Characteristics | Sleep Duration | |
Sleep Duration – PSQI (min) | 387.10 (100.5) | |
Total Sleep Time – ACT (min) | 378.7 (88.6) | |
Total Sleep Time – PSG (min) | 323.6 (96.6) | |
Sleep Continuity | ||
Sleep Efficiency – PSQI | 80.07 (17.70) | |
Sleep Efficiency – ACT | 76.74 (12.86) | |
Sleep Efficiency – PSG | 71.01 (16.25) | |
Sleep Fragmentation – ACT | 42.24 (21.27) | |
Sleep Latency – PSG | 20.92 (27.06) | |
Sleep Latency – ACT | 29.36 (37.84) | |
Sleep Quality | ||
Sleep Quality – PSQI | 1.39 (0.85) | |
Insomnia Symptoms Total (DIMS) | 1.73 (1.38) | |
Frequency of Sleep Medications | ||
None | 133 (76.9%) | |
Less than Once per week | 5 (2.9%) | |
Once or Twice per week | 5 (2.9%) | |
Three or More times per week | 30 (17.3%) | |
Pain Medications | ||
Acetaminophen | 29 (16.8%) | |
Non-Steroidal Anti-Inflammatory | 4 (3.31%) | |
Gabapentin | 6 (3.47%) | |
Daytime Sleep Characteristics | ||
Daytime Sleepiness (ESS) | 8.31 (4.34) | |
Fatigue | 29.80 (14.62) | |
Frequency of Naps over 4 days | 2.72 (2.41) | |
Snooze Time – ACT | 17.61 (18.38) |
Note. NYHA: New York Heart Association, PSQI: Pittsburgh Sleep Quality Index, ACT: Wrist Actigraphy (3 ACT nights average), PSG: Polysomnography (1 PSG night), ESS: Epworth Sleepiness Scale